Revenue Update on Cambrex Corporation(NYSE:CBM)

Cambrex Corporation(NYSE:CBM) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $118.22M. Analysts estimated a revenue of $114.85M. Earnings per share were $0.68. Analysts had estimated an EPS of $0.59.

In a different note, On May 2, 2016, Singular Research said it Terminates its rating on Cambrex Corporation.

Cambrex Corporation (CBM) made into the market gainers list on Thursdays trading session with the shares advancing 0.50% or 0.24 points. Due to strong positive momentum, the stock ended at $48.02, which is also near the day’s high of $48.95. The stock began the session at $48.02 and the volume stood at 3,35,268 shares. The 52-week high of the shares is $59.41 and the 52 week low is $29.5. The company has a current market capitalization of $1,544 M and it has 3,21,47,275 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On Jul 11, 2016, William B Korb (director) sold 3,420 shares at $55.00 per share price.Also, On May 10, 2016, Steven M Klosk (President & CEO) sold 14,005 shares at $49.00 per share price.On Mar 16, 2016, Louis J. Grabowsky (director) purchased 750 shares at $40.10 per share price, according to the Form-4 filing with the securities and exchange commission.

Cambrex Corporation (Cambrex) is a life sciences company that provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services worldwide to innovator and generic pharmaceutical companies. The Company’s customers include generic drug companies and companies that discover and commercialize small molecule human therapeutics using organic chemistry. Its business consists of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The Company’s products include active pharmaceutical ingredients (APIs) pharmaceutical intermediates and to a lesser extent other fine chemicals. Cambrex has three operating segments which are manufacturing facilities that have been aggregated as one reportable segment.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Cambrex Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cambrex Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.